Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

The genetic modification therapy market presents key opportunities in developing specialized treatments for rare, inherited, ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced the ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...

Scientists have transformed enigmatic cell structures, called vaults, into storage units for messenger-RNA molecules made in ...

Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism.

A research team led by Associate Professor Hirofumi Nishizono and graduate student Masaki Kato from the Research Support ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Programmable nucleic acid nanoparticles boost vaccine immune responses as effectively as standard adjuvants in mice while ...